Your session is about to expire
← Back to Search
CYNK-001 for Immunoproliferative Disorders
Phase 1
Waitlist Available
Research Sponsored by Celularity Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male subjects must agree to use a condom during sexual contact for at least 28 days following the CYNK-001, even if he has undergone a successful vasectomy.
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
Study Summary
This trial will study the safety and effectiveness of CYNK-001, a treatment for multiple myeloma made from NK cells derived from the placenta.
Eligible Conditions
- Immunoproliferative Disorders
- Lymphoproliferative Disorders
- Painkillers
- Sensory System Agents
- Peripheral Nervous System Agents
- Cancer
- Hemorrhagic Disorders
- Paraproteinemia
- Hemostatic Disorders
- Cardiovascular Disease
- Chemotherapy
- Multiple Myeloma
- Immune System Disorders
- Vascular Disease
- Drug Effects
- Blood Diseases
- Tumors
- Non-Narcotic Analgesics
- Blood Protein Disorder
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
Male participants must use a condom for at least 28 days after receiving the CYNK-001, even if they have had a vasectomy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Adverse Events (AE)
Dose-Limiting Toxicity (DLT)
Maximum Tolerated Dose (MTD) or Maximum Planned Dose (MPD)
+1 moreSecondary outcome measures
International Myeloma Working Group (IMWG) response
Minimal Residual Disease (MRD) Response
Progression-free survival
+5 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Phase IExperimental Treatment1 Intervention
Up to three dosing cohorts of CYNK-001 given on Day 2 or Days 2, 7, 14 post ASCT. Once MTD has been determined, the Expansion cohort will commence.
Find a Location
Who is running the clinical trial?
Celularity IncorporatedLead Sponsor
16 Previous Clinical Trials
598 Total Patients Enrolled
Adrian Kilcoyne, MDStudy DirectorCelularity Incorporated
3 Previous Clinical Trials
163 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger